A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z.

A radioligand for imaging central serotonin (5-hydroxytryptamine; 5-HT) uptake sites by positron emission tomography (PET) has yet to be developed. Such a tracer would be useful for the study of normal and altered serotonergic neurotransmission as well as for the detection of serotonergic neurotoxicity. This paper describes the labeling of the highly potent serotonin (5-HT) uptake blocker, McN-5652-Z (trans-1,2,3,5,6,10 beta-hexahydro-6-[4-(methylthio)phenyl]pyrrolo-[2,1-a]-isoquinoline; racemic mixture), with 11C and the evaluation of this radiotracer in rodents with respect to its in vivo binding characteristics. In mouse brain, 11C-McN-5652-Z accumulated rapidly in regions with high densities of 5-HT uptake sites. The ratio between hypothalamus and cerebellum was 1.5:1 at 15 min and increased with time to 4.6:1 at 90 min after injection. The distribution of 11C-McN-5652 in rat brain at 60 min correlated well with regional concentrations of 5-HT uptake sites (r = 0.86). The specificity and selectivity of 11C-McN-5652 binding to the 5-HT transporter were tested by preinjecting blocking doses of known 5-HT, dopamine and norepinephrine uptake inhibitors, and a 5-HT2 receptor blocker before injection of the radiotracer. Preinjection of increasing doses of unlabeled McN-5652-Z inhibited 11C-McN-5652-Z binding in a dose-dependent fashion. These results suggest that the in vivo binding of the radiotracer was specific, selective for 5-HT uptake sites, saturable and that 11C-McN-5652-Z holds promise as a radiotracer for PET imaging of 5-HT uptake sites in the mammalian brain.

[1]  W. Vaatstra,et al.  Du 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor. , 1981, European journal of pharmacology.

[2]  D. Brunswick,et al.  Labeling in vivo of serotonin uptake sites in rat brain after administration of [3H]cyanoimipramine. , 1987, The Journal of pharmacology and experimental therapeutics.

[3]  M. Wilson,et al.  Dexfenfluramine neurotoxicity in brains of non-human primates , 1991, The Lancet.

[4]  R. Shank,et al.  Pyrroloisoquinoline antidepressants. 3. A focus on serotonin. , 1990, Journal of medicinal chemistry.

[5]  Y. Agid,et al.  Distribution of Specific High‐Affinity Binding Sites for [3H]Imipramine in Human Brain , 1981, Journal of neurochemistry.

[6]  A. Biegon,et al.  Quantitative autoradiography of [3H]nitroimipramine binding sites in rat brain , 1983, Brain Research.

[7]  U. Scheffel,et al.  In Vivo Labeling of Serotonin Uptake Sites with [3H]Paroxetine , 1989, Journal of neurochemistry.

[8]  C. Mathis,et al.  [125I]5-iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex. , 1992, European journal of pharmacology.

[9]  J. Wamsley,et al.  Localization of [3H]-imipramine binding sites in rat brain by light microscopic autoradiography. , 1983, Life sciences.

[10]  R. Griffith,et al.  cis-1,3,4,6,7,11b-Hexahydro-2-methyl-7-phenyl-2H-pyrazino[2,1-a] isoquinoline: a new atypical antidepressant. , 1984, Journal of medicinal chemistry.

[11]  R. L. Clarke,et al.  Compounds affecting the central nervous system. 4. 3 Beta-phenyltropane-2-carboxylic esters and analogs. , 1973, Journal of medicinal chemistry.

[12]  Quantitative Autoradiography of [3H]Indalpine Binding Sites in the Rat Brain: II. Regional Distribution , 1985, Journal of neurochemistry.

[13]  R. Shank,et al.  Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships. , 1987, Journal of medicinal chemistry.

[14]  R. Dannals,et al.  Synthesis of a radiotracer for studying serotonin uptake sites with positron emission tomography : [11C]McN-5652-Z , 1992 .